John J. Greisch Sells 100,000 Shares of Hill-Rom Holdings, Inc. (HRC) Stock
Hill-Rom Holdings, Inc. (NYSE:HRC) CEO John J. Greisch sold 100,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the completion of the transaction, the chief executive officer now owns 230,851 shares of the company’s stock, valued at approximately $19,119,079.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Hill-Rom Holdings, Inc. (NYSE:HRC) opened at $81.84 on Friday. The stock has a market cap of $5,480.00, a price-to-earnings ratio of 21.40, a PEG ratio of 1.76 and a beta of 1.19. Hill-Rom Holdings, Inc. has a 1 year low of $54.59 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77.
Hill-Rom (NYSE:HRC) last released its quarterly earnings data on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.05. The business had revenue of $738.30 million during the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 EPS. research analysts anticipate that Hill-Rom Holdings, Inc. will post 4.26 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 15th will be given a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.72 annualized dividend and a dividend yield of 0.88%. Hill-Rom’s dividend payout ratio (DPR) is currently 36.18%.
Institutional investors have recently added to or reduced their stakes in the company. Seven Eight Capital LP purchased a new stake in Hill-Rom in the second quarter valued at $127,000. Acrospire Investment Management LLC lifted its position in Hill-Rom by 43.4% in the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after acquiring an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Hill-Rom by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 204 shares during the last quarter. Citigroup Inc. lifted its position in Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after acquiring an additional 433 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after acquiring an additional 1,367 shares during the last quarter. 82.35% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Hill-Rom from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. ValuEngine downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Saturday, November 4th. Stifel Nicolaus boosted their price target on shares of Hill-Rom from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Barclays boosted their price target on shares of Hill-Rom from $86.00 to $90.00 and gave the stock an “overweight” rating in a research note on Monday, November 6th. Finally, Needham & Company LLC dropped their price target on shares of Hill-Rom from $93.00 to $90.00 and set a “buy” rating for the company in a research note on Monday, November 6th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $89.57.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with Analyst Ratings Network's FREE daily email newsletter.